KLF5 activates the promoter of PAI-1, an inhibitor of fibrin degradation, thus contributing to ECM accumulation and leading to vascular wall thickening and cardiac hypertrophy (Nagai et al., 2003; Adnot et al., 2019). The gene discussed is KLF5; the disease is cardiac hypertrophy.